157 results about "Glycolysis" patented technology

The invention discloses a rice large-scale metabolism regulator DGP1 and crop metabolism quality design. The invention finds that the structural domain of the rice DGP1 family protein TIGR01589 targets a plurality of metabolic enzymes and promotes the metabolic enzymes to be transferred to a cell nucleus; the structural domain also has an intervention effect on a light breathing pathway by changing the composition of a glycine decarboxylase compound in mitochondria. Based on a molecular mechanism of DGP1, a chimeric protein ST containing a conservative structural domain and coupled with a chloroplast positioning signal is designed, and genetic engineering modification of pakchoi is realized. The modification strategy not only can guide substrate flow of a central glycolysis pathway to flavonoid biosynthesis, but also can promote accumulation of saccharides derived from photosynthetic products in leaves.

The present invention relates to a process for depolymerizing a polyester feedstock comprising opaque PET, which comprises: a) a conditioning step; b) a step of glycolysis, operated at between 180 and 400° C., a residence time of from 0.1 to 10 h in the presence of diol; c) a diol separation step, at a temperature of between 100 and 250° C., a pressure lower than that of step b) and producing a diol effluent and an effluent rich in monomers; d) a step of separating into a heavy impurities effluent and a prepurified monomers effluent, at a temperature of less than 250° C. and a pressure of less than 0.001 MPa and a residence time of less than 10 min; e) a step of decolourizing the prepurified monomers effluent, by adsorption of a mixture comprising between 20% and 90% by weight of the prepurified monomers effluent and a solvent, at a temperature of between 100 and 200° C., a pressure of between 0.1 and 1.0 MPa and in the presence of at least one adsorbent.

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K17 site succinylation modification and application. Experiments show that the 17-site lysine of the PGK1 protein has succinylation modification (PGK1 K17su), and the existence of the modification is confirmed through a specific succinylation modified antibody for the first time. Further, it is found that PGK1 K17su can weaken lung cancer cell oxidative phosphorylation and promote glycolysis metabolism by inhibiting lung cancer cell mitochondrial generation, and functional experiments prove that PGK1 K17 succinylation modification promotes proliferation and migration of lung cancer cells.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention relates to the technical field of osteoarthritis drugs, particularly discloses an application of DDX5-K45mRNA in preparation of drugs for treating and / or relieving osteoarthritis, and provides a drug delivery system for targeting chondrocytes at the same time, research finds that when DDX5-K45mRNA is added into the chondrocytes, the drug delivery system can be used for treating and / or relieving osteoarthritis. The medicine can restore DDX5-K45 lactic acid, block NF-kappa B inflammation signals, correct metabolic reprogramming (such as inhibition of abnormal glycolysis), and up-regulate cartilage protection factors such as COL2A1 and the like. The LNP is utilized to efficiently deliver DDX5-K45mRNA to cartilage cells, endogenous lactic acid modification defects are directly supplemented, the cartilage protection function of DDX5 is reconstructed, inflammatory response is inhibited, matrix degradation is reduced, the cartilage steady state is maintained fundamentally, and long-acting and safe OA treatment is achieved.

Quinones for use in therapeutic recovery, normalization and / or improvement of ATP in mitochondrial deficient cells, such as red blood cells, are disclosed. Particular examples are use in the treatment of erythrocystic diseases, especially in the treatment of erythrocyte metabolic defects, such as erythrocyte glycolysis defects. This treatment increases ATP in non-mitochondrial cells. Thus, the present invention relates to quinones for use in the treatment of diseases or conditions associated with or caused by a glycolytic deficiency in red blood cells.

The invention discloses antibacterial mouthwash as well as a preparation method and application thereof, and belongs to the technical field of daily chemical products. According to the invention, egg white lysozyme, ferulic acid and grape seed procyanidine are taken as core components, and the mouthwash with an efficient bacteriostatic effect is developed. And the antibacterial rates of streptococcus mutans and porphyromonas gingivalis are 96.88% and 96.30% respectively. Researches show that bacterial biofilms can be destroyed by using the mouthwash, and the biofilm quantity is reduced by 53.7% after the bacterial biofilms are treated for 24 hours; extracellular polysaccharide is inhibited, the content of water-insoluble glucan is reduced by 62.3%, and synthesis of a key cariogenic matrix is hindered; the acid production capacity is regulated and controlled, the pH change of 24-hour culture is only 1.50, and xylitol competitively inhibits glycolysis and cooperates with ferulic acid to block bacterial metabolism. The mouthwash prepared by the invention avoids the problem of enzyme activity inhibition of the ionic surfactant of the traditional mouthwash, takes effect more quickly, and provides a basis for developing natural, safe and efficient functional mouthwash.

The invention discloses application of CFB polypeptide as a target spot in preparation of diabetic nephropathy diagnosis and treatment medicines, and belongs to the technical field of biological medicines. The invention provides application of CFB (circulating fluid bed)-sourced polypeptide in preparation of a medicine for treating diabetic nephropathy and application of the CFB-sourced polypeptide as a possible target in development of a novel diabetic nephropathy biomarker. According to the invention, a complement factor B-derived polypeptide which is significantly up-regulated in diabetic nephropathy is found through deep peptidomics analysis; furthermore, a functional experiment proves that the polypeptide shows remarkable anti-fibrosis activity in kidney cells for the first time, the active oxygen level can be reduced, and an HIF-1 alpha / glycolytic pathway can be regulated and controlled.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention discloses application of thiamine in preparation of a product for treating subclinical ketosis of dairy cows, and belongs to the field of biological medicines. Tests prove that compared with dairy cows suffering from subclinical ketosis (SCK), by adding thiamine, the content of beta-hydroxybutyric acid (BHBA), the number of bacteria in milk and the number of somatic cells can be remarkably reduced, and the milk yield, the milk fat content, the acetic acid content and the A / P ratio are remarkably increased; the microbial diversity of rumen and excrement of the dairy cow can be adjusted; a metabonomics result shows that metabolite up-regulated after the thiamine is added mainly focuses on pyruvic acid metabolism, glycolysis or gluconeogenesis, tyrosine metabolism, glycerophospholipid metabolism and biosynthetic pathways of phenylalanine, tyrosine and tryptophan. The conclusion is that when thiamine is added into the SCK dairy cow, synthesis and catabolism of BHBA of an organism can be effectively regulated and controlled by adjusting the content of succinyl-coenzyme A, then subclinical ketosis is relieved, rumen fermentation is promoted, and therefore the milk yield and the milk quality are improved.

The invention discloses a camelina sativa seed meal oligosaccharide extract capable of regulating blood sugar and a preparation method of the camelina sativa seed meal oligosaccharide extract, and the camelina sativa seed meal oligosaccharide extract is extracted from camelina sativa seed meal through fermentation, heating extraction, cooling alcohol precipitation and enzymolysis. Comprising a camelina seed meal oligosaccharide extract and a cortex fraxini iridoid component extract. The cortex fraxini iridoid component extract is obtained through microwave-assisted enzymolysis extraction and purification; the invention further discloses application of the blood sugar reducing composition in blood sugar reducing food, medicine or health care products. The camelina seed meal oligosaccharide extract, the cortex fraxini iridoid component extract and the hypoglycemic composition have inhibition ability on alpha-glucosidase and alpha-amylase, can improve glucose consumption, glycogen content and glycolysis key enzyme activity, effectively improve insulin resistance, improve oxidative stress, regulate intestinal flora structure, and improve the blood sugar level, so that the hypoglycemic effect of the composition is improved. The traditional Chinese medicine is safe and non-toxic and has a good effect on treating diabetes and complications.

The invention discloses a genetically engineered bacterium for synthesizing N-acetyl blue as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium is prepared by knocking out a lactic dehydrogenase gene ldh and inserting a phosphoketolase gene xfpK on a knockout site, knocking out a pyruvate oxidase gene poxB and inserting a phosphate transacetylase gene pta on a knockout site of a microorganism for producing N-acetyl blue, and knocking out an aconitase inhibition factor gene acnR, inserting a glutamate dehydrogenase gene gdhA on a knockout site, knocking out a glutamine synthetase adenylation transferase gene glnE, and inserting an alpha-ketoglutarate dehydrogenase inhibition factor gene odhI on a knockout site to obtain the strain. According to the method, the supply of the precursor acetyl coenzyme A is enhanced by introducing a non-oxidative glycolysis pathway, the pH dynamic regulation system balances the metabolic flux, and the double breakthrough of the yield and the carbon recovery rate of the N-acetyl blue is realized by combining a two-stage fermentation process.

The invention discloses a nucleolin aptamer modified carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system as well as a preparation method and application thereof, and relates to the field of tumor treatment. The nucleolin aptamer AS1411 is coupled with glycolysis regulation nano-particles through covalent bonds, and the carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system comprises a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system and a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, the glycolysis regulation nano-particles take carboxymethyl chitosan as a carrier skeleton, the carrier skeleton is loaded with a lonidamine derivative through grafting modification, and the nano drug delivery system can synchronously entrap paclitaxel. According to the invention, a synergistic treatment system integrating active targeting, metabolic regulation and chemotherapy is constructed, and by virtue of a multi-mechanism synergistic effect, an antitumor drug for inhibiting tumor cell activity, glycolysis or tumor metabolism reprogramming is prepared; the huge potentials of overcoming the drug resistance bottleneck of traditional chemotherapy, enhancing the curative effect and reducing the toxic and side effects are shown.

The invention relates to the technical field of medicines, and particularly discloses an application of artemether in preparation of an esophageal cancer radiotherapy sensitization medicine. The invention provides the application of artemether in preparation of esophageal cancer radiotherapy sensitization drugs for the first time, and researches find that the artemether can reduce glycolytic activity of esophageal cancer cells by down-regulating expression of key proteins and genes HK2, PKM2 and LDHA in a glycolytic pathway so as to enhance esophageal squamous cell carcinoma radiotherapy sensitization. The invasion ability is inhibited, and cell apoptosis is induced, so that the radiotherapy sensitivity of esophageal cancer cells is enhanced. The artemether and radiotherapy combined treatment provided by the invention is expected to provide a promising treatment scheme for ESCC patients, and has great significance in breaking through the bottleneck of esophageal cancer radiotherapy.

The application belongs to the technical field of medicine production, and particularly relates to a preparation method and application of five deuterium-substituted glucose. The method comprises deuterium substitution of D-methyl glucoside, and demethylation of the deuterium-substituted D-methyl glucoside to obtain a target product, namely [2,3,4,6,6'-d5]-D-glucose. The preparation method of the five deuterium-substituted glucose is simple in process route, convenient to operate, mild in experimental conditions, and the synthesized five deuterium-substituted glucose is successfully applied to the description of glycolysis metabolism in a brain glioma model, which is helpful to the clinical conversion application of metabolic imaging technology.

T lymphocytes play a key role in the immune response and their functions are intimately linked to metabolic programs. During immune responses, T cells undergo a metabolic reprogramming notably characterized by an increased aerobic glycolysis. Using a quantitative phosphoproteomic approach, the inventors have identified a new transcription factor called Foxk1 as being highly phosphorylated in T cells upon T Cell Receptor (TCR) engagement. The results also indicate that Foxk1 phosphorylation and nuclear translocation is dependent of the AKT-mTOR kinase activities. Using T-cell specific Foxk1 deficient mice (Foxk1- / -), we demonstrated that Foxk1 is required for full T cell activation. Foxk1-deficient T cells exhibited reduced proliferation and cytokine secretion following TCR stimulation. Furthermore, T cells from Foxk1- / - mice were less prone to acquire an effector like phenotype than wild-type cells when challenged in vivo. Conversely, Foxk1 overexpression in T cells enhanced their effector functions in a TCR-dependent manner. In CD8+ T cells, this effect also results into enhanced cancer cell killing capacity in vitro, and improved tumor rejection in vivo. Altogether, these results indicated that Foxk1 is a major regulator of T cell metabolism and thus, of T cell effector functions. Thus, the present invention relates to host immune cells engineered to overexpress a Foxk1 polypeptide and their use of the treatment of cancer.

This application relates to the field of tumor metabolic biomarker detection technology, and discloses a method for detecting glucose metabolism biomarkers in esophageal cancer based on VAV2-related molecular characteristics. The method includes: performing immunohistochemical staining on esophageal cancer tissue samples to obtain VAV2, EIF3F, MTA1, and HIF-1α protein expression sections; scoring the immunoreaction of each section; calculating a comprehensive glucose metabolism phenotype score based on the molecular hierarchy of the VAV2-EIF3F-MTA1 / HIF-1α glucose metabolism regulatory pathway; and classifying the samples into high-glycolytic, moderate-glycolytic, and low-glycolytic types according to the comprehensive score. This application improves the accuracy and stability of glucose metabolism phenotype discrimination in esophageal cancer.

The invention discloses a method and a device for detecting the energy metabolism level of cells and organoids. According to the detection method disclosed by the invention, the acidification rate and the oxygen consumption rate of the extracellular microenvironment are obtained through signal response of hydrogen ions and the dissolved oxygen sensing electrode, and meanwhile, a dynamic detection microcavity is constructed by utilizing a metabolism detection device, so that the sensitivity and the accuracy of measurement are improved. By adopting different drug intervention schemes, the energy metabolism pathway of the cells can be regulated and controlled, so that the evaluation of the two energy metabolism pathways of glycolysis and aerobic respiration of the cells is realized. The in-situ and high-sensitivity cell energy metabolism detection method and device are provided by detecting the concentration change of the specific analyte of the extracellular microenvironment, the method has the universality of two-dimensional and three-dimensional cell models, a brand new platform is provided for scientific research and drug effect screening based on an in-vitro model, and the application prospect is wide.

The invention relates to a composition and method to increase survival of fish following catch-and-release events. The composition comprises an energy substrate and a hydrocolloid. The composition may comprise an application-safe buffer. The energy substrate may be a glycolysis metabolite, a Krebs cycle metabolite, an amino acid, a nitric oxide donor, a triglyceride, and mixtures thereof. The hydrocolloid may be a polysaccharide. The composition may include an oxygenated substrate, a trophic hormone, a stress reducing additive, a chelating agent, an antimicrobial preservative, and a color additive, and mixtures thereof. The method comprises after catching the fish, applying the composition to the fish and releasing the fish back into the wild. The composition may alternatively be mixed with a flotant or a cured polymer in the shape of a lure such that composition may be dispersed onto the oxygen exchange tissue of the fish when it is caught.

The invention relates to the field of biomedical detection, and particularly discloses a kit for detecting chromosome alloploid necrotic cells and application thereof, the kit comprises a metabolism tracer, a lactic acid specific binding probe connected with a detectable marker, a membrane-impermeable nucleic acid dye and a DNA metal mutual embedding agent; the use method comprises the following steps: co-incubating a to-be-detected sample and the metabolic tracer agent to enable cells to generate labeled lactic acid; sequentially contacting with a lactic acid probe, a membrane-impermeable nucleic acid dye and a DNA metal mutual embedding agent; and finally analyzing the cell state by detecting each signal. According to the method, the metabolic activity, the cell dead and living state and the DNA ploidy are synchronously detected on the single cell level, the special cell subpopulation with high glycolytic activity, necrosis characteristics and chromosome heteroploidy can be accurately recognized, and the technical problem that multi-dimensional cell information is difficult to integrate and analyze is solved; the kit has important application value in cancer diagnosis, prognosis evaluation, curative effect monitoring and drug screening.

A method for producing bis(2-hydroxyethyl)terephthalate is disclosed. The method includes recovering and reusing ethylene glycol with an acetate removed, after the glycolysis of a waste polyester. According to the method, an acetate is not concentrated even though ethylene glycol is reused in a continuous process, leading to bis(2-hydroxyethyl)terephthalate with excellent purity and quality.

The invention discloses a keloid treatment gel material capable of reducing lactic acid generation, and belongs to the technical field of keloid treatment. The material is prepared by the following steps: firstly, carrying out esterification on 9-oxabicyclo [3.3. 1] nonane-2, 6-diol and S-allyl-L-cysteine to obtain an intermediate A, and then carrying out Schiff base reaction on the intermediate A and 5-methoxy heliotropin to obtain an intermediate B containing double bonds; then, copolymerizing with methylacryloylated chitosan and polyethylene glycol diacrylate under photo-initiation to form a cross-linked network structure; finally, active ingredients such as quercetin-3-O-glucuronide and luteolin-3 '-glucuronide are included, and auxiliary materials such as a humectant and a preservative are added, so that the composition is prepared. The gel has a slow release function, can effectively inhibit glycolysis, reduce lactic acid generation, scavenge free radicals and regulate inflammation and fibrosis microenvironment, has good biocompatibility and oxidation response drug release characteristics, and is suitable for prevention and treatment of keloids.

The invention provides an application and a method of GSH in promoting mature differentiation of hiPSC-CMs, and the method is characterized in that in the process of directionally differentiating the hiPSC-CMs into the hiPSC-CMs, an effective dose of GSH is added into a differential medium, and the optimal concentration is 20-100 [mu] M. According to the invention, through simple and economical exogenous supplement of GSH, maturation of hiPSC-CMs is systematically promoted from multiple dimensions, including enhancement of intracellular anti-oxidation defense capability; energy metabolism is promoted to be converted from glycolysis to oxidative phosphorylation; up-regulating expression of cardiac muscle cell specific structural protein and calcium ion channel related genes; mitochondrial biological generation and functions are promoted; and the cell morphological structure is induced to develop to a mature phenotype. The method is simple and convenient to operate and high in biocompatibility, the hiPSC-CMs with mature functions can be stably obtained, and a high-quality cell source is provided for application of the hiPSC-CMs in the fields of heart disease modeling, drug cardiotoxicity screening and the like.

This invention discloses a cell proliferation culture device, belonging to the field of biomedical experimental equipment technology, comprising: a culture body, a microporous membrane, a microfluidic channel, a temperature control module, a sensor module, a sampler, and a control unit. The cell proliferation culture device of this invention can dynamically monitor the glucose consumption rate and lactate production rate during cell proliferation in real time, supports pollution-free dynamic sampling and rapid microenvironment switching, and is particularly suitable for studying the interaction between SIRT2 and HKII to regulate aerobic glycolysis and growth proliferation of colorectal cancer cells. It also has advantages such as real-time monitoring, high sensitivity, pollution-free sampling, and dynamic microenvironment control.

The invention discloses application of triptolide ketone in preparation of a medicine for treating sepsis lung injury, and belongs to the technical field of biological medicine. Aiming at the problems that traditional chemical synthetic drugs may cause a large amount of sequelae and antibiotic abuse, and triptolide may cause liver and kidney injury when treating sepsis, research finds that triptolide can be used for treating sepsis lung injury, and can be used for treating sepsis lung injury. According to the application, the protein expression level of HIF-1alpha in proinflammatory activated macrophages is lowered, so that aerobic glycolysis is inhibited, and the effect of treating sepsis lung injury is achieved. Compared with the triptolide alcohol, the triptolide ketone does not cause liver and kidney injury while playing a role in treating the sepsis lung injury, and the curative effect of the triptolide ketone is equivalent to that of the existing medicine 2ME2 for treating the sepsis lung injury, so that the triptolide ketone has important application potential clinically, and can be used for preparing medicines for treating the sepsis lung injury. And a theoretical basis is provided for clinically developing medicines for treating sepsis lung injury.

The present application relates to the technical field of biological medicine, and particularly relates to application of a nucleic acid vector encoding a macrophage monocarboxylate transporter MCT1 in preparation of a pharmaceutical composition for promoting corneal nerve regeneration and recovery of corneal sensitivity after corneal nerve injury. The present application finds that after corneal nerve injury, increasing the level of macrophage MCT1 can drive the change of the metabolic mode of macrophages to the direction of enhanced oxidative phosphorylation and reduced glycolysis, reduce the expression of local pro-inflammatory related factors, and increase the level of pro-regeneration factors and neurotrophic factors, thereby improving the regeneration of corneal nerve structure and the recovery of sensory function. Therefore, a macrophage-targeted or macrophage-biased expression vector containing a nucleic acid sequence encoding MCT1 can be used for preparation of a pharmaceutical composition for treating corneal nerve injury.

The invention relates to the field of biological medicines, and discloses application of a DIRAS2 inhibitor in preparation of a medicine for preventing and / or treating diseases characterized by glycolysis enhancement. According to the invention, RNA-seq sequencing and cell and animal model experiments are utilized to verify and explore the influence of DIRAS2 expression on glycolysis of oral precancerous lesion cells, and it is clear that cell glycolysis can be significantly inhibited by inhibiting DIRAS2, so that cells are interfered to obtain energy to maintain survival. The method can be applied to treatment of all diseases related to glycolytic phenotype change, and cell glycolysis is interfered by regulating and controlling DIRAS2 expression in a targeted manner, so that the disease treatment effect is improved. The invention provides a new target for clinically intervening oral leukoplakia progress from the perspective of targeted molecule development and reducing the morbidity of oral cancer, and has important scientific and practical significance.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

The invention discloses a copper-manganese alloy drug loading system and a preparation method and application thereof.The preparation method of the copper-manganese alloy drug loading system at least comprises the following steps that S1, gas-atomized copper-manganese powder serves as a raw material, the 3D printing technology is used for printing the gas-atomized copper-manganese powder, and a copper-manganese alloy precursor is obtained; s2, the copper-manganese alloy precursor is placed in a dealloying solution for dealloying, and the copper-manganese alloy of the porous nanostructure is obtained; and S3, loading an anti-tumor drug on the copper-manganese alloy with the porous nanostructure to obtain the copper-manganese alloy drug loading system. The copper-manganese alloy drug delivery system selectively releases manganese ions, can widely inhibit expression of cancer cell glycolysis related genes, hinder cancer cell glycolysis, mediate cancer cell pyroptosis and activate anti-tumor immunity, KHK-IN-2 can inhibit cancer-promoting macrophage fructose metabolism, finally macrophage metabolism-immune reprogramming is achieved, and the anti-tumor curative effect is further enhanced.